Staff directory Paula Alfonso Triguero

Paula Alfonso Triguero

Doctoral Student
FPI 2019
Nanostructured Functional Materials



  • Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?

    Alfonso-Triguero, P; Lorenzo, J; Candiota, AP; Arus, C; Ruiz-Molina, D; Novio, F Nanomaterials; 13 (10) 2023. 10.3390/nano13101619. IF: 5.300


  • Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

    Ruiz-Molina, D; Mao, XM; Alfonso-Triguero, P; Lorenzo, J; Bruna, J; Yuste, VJ; Candiota, AP; Novio, F Cancers; 14 (19) 2022. 10.3390/cancers14194960. IF: 6.575

  • Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment

    Mao X., Wu S., Calero-Pérez P., Candiota A.P., Alfonso P., Bruna J., Yuste V.J., Lorenzo J., Novio F., Ruiz-Molina D. Cancers; 14 (2, 410) 2022. 10.3390/cancers14020410. IF: 6.639

    Glioblastoma is the most malignant and frequently occurring type of brain tumors in adults. Its treatment has been greatly hampered by the difficulty to achieve effective therapeutic concentration in the tumor sites due to its location and the blood–brain barrier. Intranasal administration has emerged as an alternative for drug delivery into the brain though mucopenetration, and rapid mucociliary clearance still remains an issue to be solved before its implementation. To address these issues, based on the intriguing properties of proteins secreted by mussels, polyphenol and catechol functionalization has already been used to promote mucopenetration, intranasal delivery and transport across the blood–brain barrier. Thus, herein we report the synthesis and study of complex 1, a Pt(IV) prodrug functionalized with catecholic moieties. This complex considerably augmented solubility in contrast to cisplatin and showed a comparable cytotoxic effect on cisplatin in HeLa, 1Br3G and GL261 cells. Furthermore, preclinical in vivo therapy using the intranasal administration route suggested that it can reach the brain and inhibit the growth of orthotopic GL261 glioblastoma. These results open new opportunities for catechol-bearing anticancer prodrugs in the treatment for brain tumors via intranasal administration. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.